EA201491623A1 - Замещенные пирролидин-2-карбоксамиды - Google Patents

Замещенные пирролидин-2-карбоксамиды

Info

Publication number
EA201491623A1
EA201491623A1 EA201491623A EA201491623A EA201491623A1 EA 201491623 A1 EA201491623 A1 EA 201491623A1 EA 201491623 A EA201491623 A EA 201491623A EA 201491623 A EA201491623 A EA 201491623A EA 201491623 A1 EA201491623 A1 EA 201491623A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carboxamides
compounds
substituted pyrrolidin
pyrrolidin
substituted
Prior art date
Application number
EA201491623A
Other languages
English (en)
Other versions
EA025557B1 (ru
Inventor
Дэвид Джозеф Бартковиц
Синь-Цзе Чу
Бин Тан Ву
Чуньлинь Чжао
Даниэль Фишлок
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of EA201491623A1 publication Critical patent/EA201491623A1/ru
Publication of EA025557B1 publication Critical patent/EA025557B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

Предложены соединения формулыгде X, Y, Z, R, R, Rи Rтаковы, как раскрыто в настоящем описании, их энантиомеры и фармацевтически приемлемые соли и эфиры; а также способы получения таких соединений, фармацевтические композиции, включающие указанные соединения, и их применение в лечении рака.
EA201491623A 2012-03-15 2013-03-12 Замещенные пирролидин-2-карбоксамиды EA025557B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611200P 2012-03-15 2012-03-15
PCT/EP2013/054920 WO2013135648A1 (en) 2012-03-15 2013-03-12 Substituted pyrrolidine-2-carboxamides

Publications (2)

Publication Number Publication Date
EA201491623A1 true EA201491623A1 (ru) 2014-12-30
EA025557B1 EA025557B1 (ru) 2017-01-30

Family

ID=47844360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491623A EA025557B1 (ru) 2012-03-15 2013-03-12 Замещенные пирролидин-2-карбоксамиды

Country Status (28)

Country Link
US (1) US8993614B2 (ru)
EP (1) EP2825528B1 (ru)
JP (1) JP6125546B2 (ru)
KR (1) KR20140138165A (ru)
CN (1) CN104271554B (ru)
AR (1) AR090328A1 (ru)
AU (1) AU2013203662B2 (ru)
BR (1) BR112014018959A8 (ru)
CA (1) CA2860781A1 (ru)
CL (1) CL2014001858A1 (ru)
CO (1) CO6990736A2 (ru)
CR (1) CR20140399A (ru)
DK (1) DK2825528T3 (ru)
EA (1) EA025557B1 (ru)
ES (1) ES2634290T3 (ru)
HK (1) HK1200830A1 (ru)
HU (1) HUE032864T2 (ru)
IL (1) IL234173A (ru)
MX (1) MX2014010942A (ru)
NZ (1) NZ626505A (ru)
PE (1) PE20142185A1 (ru)
PH (1) PH12014501542B1 (ru)
PL (1) PL2825528T3 (ru)
SG (1) SG11201404344XA (ru)
SI (1) SI2825528T1 (ru)
TW (1) TWI586648B (ru)
UA (1) UA113541C2 (ru)
WO (1) WO2013135648A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014014229A (es) 2012-05-30 2015-02-17 Hoffmann La Roche Pirrolidina-2-carboxamidas sustituidas.
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
AU2014301324A1 (en) * 2013-06-24 2015-12-10 F. Hoffmann-La Roche Ag Stable intravenous formulation
EP3017061B1 (en) 2013-07-03 2019-01-02 F. Hoffmann-La Roche AG Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3077004B1 (en) * 2013-12-05 2020-02-19 F.Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
KR20160138307A (ko) * 2014-04-15 2016-12-02 에프. 호프만-라 로슈 아게 약학적으로 활성인 화합물의 고체 형태
KR20170030474A (ko) * 2014-05-22 2017-03-17 더 유니버시티 오브 시드니 오메가―3 유사체
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
CN104496822B (zh) * 2014-12-15 2016-10-26 扬州三友合成化工有限公司 一种1-氯乙基环己基丙基碳酸酯的制备方法
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
WO2018027477A1 (zh) * 2016-08-08 2018-02-15 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
CN107698598B (zh) * 2016-08-08 2019-06-21 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
KR20200100120A (ko) * 2017-12-20 2020-08-25 앤젝스 파마수티컬, 인크. 멀티키나제 억제제로서의 카바메이트 및 우레아 화합물
CN114230561B (zh) * 2020-09-09 2024-03-19 中国人民解放军海军军医大学 一种mdm2抑制剂类小分子化合物及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
DE69120141T2 (de) 1990-03-28 1996-11-28 Nippon Oils & Fats Co Ltd Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
AU1313695A (en) 1993-12-14 1995-07-03 Sandoz Ltd. Pharmaceutical compositions containing alkyl polyoxyalkylene carboxylates
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc L Pegylationsverfahren
AU9402198A (en) 1997-09-26 1999-04-23 Becton Dickinson & Company Preparing conjugates using polyethylene glycol linkers
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2002096977A1 (fr) 2001-05-30 2002-12-05 Nanocarrier Co., Ltd. Procede de liaison d'une substance a incorporer a une terminaison polymere
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
WO2003061577A2 (en) 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005094897A2 (en) 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
JP4920593B2 (ja) 2004-10-25 2012-04-18 インテザイン テクノロジーズ, インコーポレイテッド ヘテロ二官能性ポリ(エチレングリコール)およびそれらの使用
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
US7560588B2 (en) 2006-04-27 2009-07-14 Intezyne Technologies, Inc. Poly(ethylene glycol) containing chemically disparate endgroups
WO2008109783A2 (en) 2007-03-06 2008-09-12 The Regents Of The University Of California Detecting spin perturbations using magnetic resonance imaging
CN101357986B (zh) 2007-06-13 2013-06-05 康达医药科技有限公司 聚乙二醇功能性衍生物和制造方法
WO2009128789A1 (en) 2008-04-17 2009-10-22 Agency For Science, Technology And Research Vesicles for intracellular drug delivery
WO2009155431A1 (en) 2008-06-18 2009-12-23 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
PL2300514T3 (pl) 2008-07-14 2016-09-30 Sposób syntezowania zasadniczo monodyspersyjnej mieszaniny oligomerów
AU2009282747B2 (en) 2008-08-22 2015-04-02 Takeda Pharmaceutical Company Limited Polymeric benzyl carbonate-derivatives
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
WO2010151269A1 (en) 2009-06-26 2010-12-29 Biotic Laboratories, Inc. Para-xylylene based multilayer drug elution devices
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
CN101991860B (zh) 2010-11-08 2013-06-19 中国药科大学 泊洛沙姆-羧酸类药物偶联物及其制备方法与应用
WO2012065022A2 (en) 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
JP5918274B2 (ja) 2011-02-02 2016-05-18 オンタリオ インスティテュート フォー キャンサー リサーチ 薬物送達のためのセルロース系ナノ粒子
US9212258B2 (en) 2011-02-23 2015-12-15 The Board Of Trustees Of The University Of Illinois Amphiphilic dendron-coils, micelles thereof and uses
CN102247602B (zh) 2011-06-13 2013-01-02 中山大学 一种超分子水凝胶双重药物载体及其制备方法和应用
US20130052130A1 (en) 2011-08-30 2013-02-28 University Of Washington Branched Discreet PEG Constructs
MX2014014229A (es) * 2012-05-30 2015-02-17 Hoffmann La Roche Pirrolidina-2-carboxamidas sustituidas.

Also Published As

Publication number Publication date
CN104271554B (zh) 2016-11-23
BR112014018959A8 (pt) 2017-07-11
JP6125546B2 (ja) 2017-05-10
PE20142185A1 (es) 2014-12-29
MX2014010942A (es) 2014-11-14
TW201341357A (zh) 2013-10-16
CL2014001858A1 (es) 2014-09-26
HUE032864T2 (en) 2017-11-28
PL2825528T3 (pl) 2017-09-29
PH12014501542A1 (en) 2014-09-22
JP2015512890A (ja) 2015-04-30
TWI586648B (zh) 2017-06-11
CO6990736A2 (es) 2014-07-10
ES2634290T3 (es) 2017-09-27
AR090328A1 (es) 2014-11-05
IL234173A (en) 2017-08-31
SG11201404344XA (en) 2014-10-30
WO2013135648A1 (en) 2013-09-19
US20130244958A1 (en) 2013-09-19
PH12014501542B1 (en) 2014-09-22
HK1200830A1 (en) 2015-08-14
KR20140138165A (ko) 2014-12-03
DK2825528T3 (en) 2017-08-14
EP2825528B1 (en) 2017-05-24
BR112014018959A2 (ru) 2017-06-20
EP2825528A1 (en) 2015-01-21
UA113541C2 (xx) 2017-02-10
CA2860781A1 (en) 2013-09-19
AU2013203662B2 (en) 2016-04-14
SI2825528T1 (sl) 2017-08-31
CN104271554A (zh) 2015-01-07
NZ626505A (en) 2016-04-29
CR20140399A (es) 2014-10-07
US8993614B2 (en) 2015-03-31
EA025557B1 (ru) 2017-01-30
AU2013203662A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
IN2014MN02598A (ru)
IN2014MN02652A (ru)
IN2014MN02657A (ru)
EA201690989A1 (ru) Ингибиторы syk
UA111770C2 (uk) Інгібітори бромдомену
IN2015DN01119A (ru)
IN2014MN02658A (ru)
UA107954C2 (en) Substituted pyrrolidin-2-carboxamide
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201591024A1 (ru) Димерные соединения
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201401062A1 (ru) Бициклические пиразиноновые производные
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
EA201600434A1 (ru) Применение производных бензимидазолпролина
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
EA201891804A1 (ru) Тетрациклиновые соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU